Showing 4401-4410 of 5771 results for "".
- Janssen Acquires Rights to Hemera Biosciences Investigational Gene Therapy for Late-Stage AMDhttps://modernod.com/news/janssen-acquires-rights-to-hemera-biosciences-investigational-gene-therapy-for-late-stage-amd/2478615/Janssen Pharmaceuticals announced the acquisition of rights to Hemera Biosciences’s investigational gene therapy HMR59, administered as a one-time, outpatient, intravitreal injection to help preserve vision in patients with geographic atrophy. Financial terms of the transaction with
- Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)https://modernod.com/news/oyster-point-pharma-submits-a-phase-2-clinical-trial-protocol-to-evaluate-oc-01-nasal-spray-for-neurotrophic-keratitis-nk/2478616/Oyster Point Pharma announced it has submitted to the FDA a protocol to initiate a clinical study in adult patients with neurotrophic keratitis (NK). The submission was made to Oyster Point’s investigational new drug (IND) for OC-01 (varenicline) nasal spray in dry eye disea
- Roche Receives FDA Emergency Use Authorization for New COVID-19 Antibodies Testhttps://modernod.com/news/roche-receives-fda-emergency-use-authorization-for-new-covid-10-antibodies-test/2478610/Roche announced that its Elecsys Anti-SARS-CoV-2 S antibody test has received Emergency Use Authorization (EUA) from the FDA. The semi-quantitative serology (blood) test can be used to measure the level of antibodies in people who have been exposed to the SARS-CoV-2 virus. The new test tar
- ViGeneron and WuXi Advanced Therapies Enter Strategic Manufacturing Partnership for Next-Generation Ophthalmic Gene Therapyhttps://modernod.com/news/vigeneron-and-wuxi-advanced-therapies-enter-strategic-manufacturing-partnership-for-next-generation-ophthalmic-gene-therapy/2478606/ViGeneron and WuXi Advanced Therapies announced a partnership to accelerate production for the clinical development of VG901, a next-generation ophthalmic gene therapy program. ViGeneron’s gene therapy pipeline addresses ophthalmic diseases with high unmet medical needs. Its lead pro
- Alcon Canada to Launch a Professional Line of Systane Ultra Hydration Lubricant Eye Drops Preservative Freehttps://modernod.com/news/alcon-canada-to-launch-a-professional-line-of-systane-ultra-hydration-lubricant-eye-drops-preservative-free/2478607/Alcon announced the Canadian launch of the newest addition to its portfolio of dry eye products—a professional line of Systane Ultra Hydration Lubricant Eye Drops Preservative Free. These new eye drops contain both hyaluronic acid (HA) and HP-Guar, a combination of ingredients shown to offer long
- New Survey Finds Critical Need for Education on Cataracts and Modern Treatment Optionshttps://modernod.com/news/new-survey-finds-critical-need-for-education-on-cataracts-and-modern-treatment-options/2478601/Johnson & Johnson Vision announced findings from a new survey that assessed awareness of cataracts among adults around the world. Cataracts are the leading cause of blindness globally,[1] with more than 90% of people developing cataracts by age
- Alcon Joins Health Care Alliance for Patient Safetyhttps://modernod.com/news/alcon-joins-health-care-alliance-for-patient-safety/2478602/The Health Care Alliance for Patient Safety (APS) announced Alcon as its newest member. “APS partners and patient safety advocates are excited to have Alcon join our effort to advance patient safety and strengthen the doctor-patient relationship, which is the foundation of personalized hea
- John Weiss Secures Exclusive UK Distributorship for VRmagic’s Eyesi Surgical Medical Simulatorhttps://modernod.com/news/john-weiss-secures-exclusive-uk-distributorship-for-vrmagics-eyesi-surgical-medical-simulator/2478600/John Weiss & Son has announced it has secured an exclusive distributorship for the VRmagic Eyesi Surgical medical simulator. VRmagic was established in 2001 and is a provider of virtual and augmented reality technology in medical training. The solutions developed by VRmagic permit a re
- Moderna’s mRNA COVID-19 Vaccine 94.1% Effective at Final Analysishttps://modernod.com/news/modernas-mrna-covid-19-vaccine-94-1-effective-at-final-analysis/2478596/Moderna announced Monday that the primary efficacy analysis of the phase 3 COVE study showed that its experimental mRNA-based COVID-19 vaccine mRNA-1273 had an efficacy rate of 94.1%, confirming the level observed at the first interim analysis. The company noted that the latest data were based on
- CORE and Myopia Profile Form Alliance to Expand Clinical Research and Professional Education Capabilitieshttps://modernod.com/news/core-and-myopia-profile-form-alliance-to-expand-clinical-research-and-professional-education-capabilities/2478595/The Centre for Ocular Research & Education (CORE) and Myopia Profile announced an alliance designed to expand both organizations’ services and reach. The affiliation aims to grow CORE’s extensive clinical research capabilities, adding expertise in specialty lenses, gas permeable, orthokerato